Articles from Immunome, Inc.
![](https://mms.businesswire.com/media/20250131863394/en/2369537/22/Immunome_Logo_Email.jpg)
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 shares, at a price to the public of $7.75 per share. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, were $172.5 million. All of the shares in the offering were sold by Immunome.
By Immunome, Inc. · Via Business Wire · January 31, 2025
![](https://mms.businesswire.com/media/20250129234101/en/2367688/22/Immunome_Logo_Email.jpg)
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 19,354,839 shares of its common stock at a price to the public of $7.75 per share. All of the shares are to be sold by Immunome.
By Immunome, Inc. · Via Business Wire · January 29, 2025
![](https://mms.businesswire.com/media/20250129118169/en/2367268/22/Immunome_Logo_Email.jpg)
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $125.0 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
By Immunome, Inc. · Via Business Wire · January 29, 2025
![](https://mms.businesswire.com/media/20250113464890/en/2351027/22/Immunome_Logo_Email.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 9:45 a.m. PT.
By Immunome, Inc. · Via Business Wire · January 13, 2025
![](https://mms.businesswire.com/media/20250102420836/en/2342546/22/Immunome_Logo_Email.jpg)
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 45,000 shares of common stock to four new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
By Immunome, Inc. · Via Business Wire · January 2, 2025
![](https://mms.businesswire.com/media/20241202157049/en/2320482/22/Immunome_Logo_Email.jpg)
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 2, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 210,500 shares of common stock to 15 new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
By Immunome, Inc. · Via Business Wire · December 2, 2024
![](https://mms.businesswire.com/media/20241127476225/en/2317037/22/Immunome_Logo_Email.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome’s management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:30 p.m. Eastern time.
By Immunome, Inc. · Via Business Wire · November 27, 2024
![](https://mms.businesswire.com/media/20241113523555/en/2304062/22/Immunome_Logo_Email.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.
By Immunome, Inc. · Via Business Wire · November 13, 2024
![](https://mms.businesswire.com/media/20241105740255/en/2294071/22/Immunome_Logo_jpg.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern Time.
By Immunome, Inc. · Via Business Wire · November 5, 2024
![](https://mms.businesswire.com/media/20241101678965/en/2292022/22/Immunome_Logo_TM_Email.jpg)
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 378,800 shares of common stock to 14 new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
By Immunome, Inc. · Via Business Wire · November 1, 2024
![](https://mms.businesswire.com/media/20241029209009/en/2286986/22/Immunome_Logo_TM_Email.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising preclinical data for IM-1021 and the associated proprietary ADC payload HC74. The results were presented in a poster entitled “Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload” at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24, 2024.
By Immunome, Inc. · Via Business Wire · October 29, 2024
![](https://mms.businesswire.com/media/20241018936943/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24, 2024.
By Immunome, Inc. · Via Business Wire · October 18, 2024
![](https://mms.businesswire.com/media/20241008310198/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company.
By Immunome, Inc. · Via Business Wire · October 8, 2024
![](https://mms.businesswire.com/media/20241008829262/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 3, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 851,400 shares of common stock to 25 new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
By Immunome, Inc. · Via Business Wire · October 8, 2024
![](https://mms.businesswire.com/media/20240913809373/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster with updated results from the RINGSIDE Phase 2 clinical trial of AL102 for the treatment of desmoid tumors at the European Society of Medical Oncology (ESMO) Congress, being held in Barcelona from 13-17 September 2024.
By Immunome, Inc. · Via Business Wire · September 13, 2024
![](https://mms.businesswire.com/media/20240829122114/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 P.M. Eastern Time.
By Immunome, Inc. · Via Business Wire · August 29, 2024
![](https://mms.businesswire.com/media/20240812692309/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the second quarter ended June 30, 2024, and provided a business update.
By Immunome, Inc. · Via Business Wire · August 12, 2024
![](https://mms.businesswire.com/media/20240725411821/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today provided an update on recent business development activity, including three recently closed transactions that are expected to enhance the company’s antibody-drug conjugate (ADC) capabilities. Immunome acquired worldwide, exclusive rights to:
By Immunome, Inc. · Via Business Wire · July 25, 2024
![](https://mms.businesswire.com/media/20240627833859/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as Chief Technical Officer. Dr. Tsai has nearly three decades of experience in product development, process optimization, and manufacturing, particularly in the area of antibody-drug conjugates (ADCs).
By Immunome, Inc. · Via Business Wire · June 27, 2024
![](https://mms.businesswire.com/media/20240520133699/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related assets from Atreca, Inc. Under the terms of the agreement, Immunome paid Atreca $5.5 million upfront, and Atreca will be eligible for up to $7.0 million in clinical development milestones. Immunome received the rights to 28 antibodies as well as certain materials.
By Immunome, Inc. · Via Business Wire · May 20, 2024
![](https://mms.businesswire.com/media/20240517911577/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome’s Interim Chief Financial Officer since January 2024.
By Immunome, Inc. · Via Business Wire · May 17, 2024
![](https://mms.businesswire.com/media/20240514845046/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
By Immunome, Inc. · Via Business Wire · May 14, 2024
![](https://mms.businesswire.com/media/20240508531812/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 10:40 A.M. Pacific Time.
By Immunome, Inc. · Via Business Wire · May 8, 2024
![](https://mms.businesswire.com/media/20240502691216/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and business development, alliance management, and commercial strategy.
By Immunome, Inc. · Via Business Wire · May 2, 2024
![](https://mms.businesswire.com/media/20240405536897/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP). Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024, which is taking place April 5-10 in San Diego, California.
By Immunome, Inc. · Via Business Wire · April 5, 2024
![](https://mms.businesswire.com/media/20240328336295/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments.
By Immunome, Inc. · Via Business Wire · March 28, 2024
![](https://mms.businesswire.com/media/20240326907197/en/405005/5/Immunome_Logo.jpg)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of AL102 and related drug candidate AL101 from Ayala Pharmaceuticals, Inc.
By Immunome, Inc. · Via Business Wire · March 26, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024 at 4:20 p.m. ET.
By Immunome, Inc. · Via Business Wire · March 7, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:50 p.m. ET.
By Immunome, Inc. · Via Business Wire · March 1, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors.
By Immunome, Inc. · Via Business Wire · February 20, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares, at a price to the public of $20.00 per share. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, are $230.0 million. All of the shares in the offering were sold by Immunome.
By Immunome, Inc. · Via Business Wire · February 16, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $20.00 per share. All of the shares are to be sold by Immunome.
By Immunome, Inc. · Via Business Wire · February 13, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
By Immunome, Inc. · Via Business Wire · February 13, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments. Completion of the transaction is subject to customary conditions including Ayala obtaining the requisite stockholder approval.
By Immunome, Inc. · Via Business Wire · February 6, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome management will present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8 at 9:30 a.m. ET.
By Immunome, Inc. · Via Business Wire · February 5, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025, and Zentalis’ proprietary ADC platform technology.
By Immunome, Inc. · Via Business Wire · January 8, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer. Mr. Roberts has over three decades of experience in product development, global manufacturing, and commercialization of novel pharmaceutical products.
By Immunome, Inc. · Via Business Wire · January 4, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 8 at 7:30 a.m. PT.
By Immunome, Inc. · Via Business Wire · January 3, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Carol A. Schafer to its Board of Directors. Ms. Schafer has more than 25 years of experience in investment banking and equity capital markets and has served as a corporate director for multiple public companies.
By Immunome, Inc. · Via Business Wire · January 2, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (Nasdaq: BCEL) to acquire a collection of antibody-related assets and materials.
By Immunome, Inc. · Via Business Wire · December 26, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET.
By Immunome, Inc. · Via Business Wire · November 10, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
By Immunome, Inc. · Via Business Wire · November 9, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals.
By Immunome, Inc. · Via Business Wire · November 8, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer. Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research.
By Immunome, Inc. · Via Business Wire · October 19, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it has completed its previously announced merger with Morphimmune.
By Immunome, Inc. · Via Business Wire · October 3, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
By Immunome, Inc. · Via Business Wire · August 9, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled “IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation,” in the peer-reviewed journal mAbs. The data in the article demonstrates that antibody-based targeting of IL-38 reactivates the immunostimulatory anti-tumor mechanisms within the tumor microenvironment in preclinical testing.
By Immunome, Inc. · Via Business Wire · May 23, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
By Immunome, Inc. · Via Business Wire · May 5, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update.
By Immunome, Inc. · Via Business Wire · March 16, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the 13th Annual World ADC London conference, taking place from March 13-16, 2023.
By Immunome, Inc. · Via Business Wire · March 9, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that discovers novel target-antibody pairs through its unbiased interrogation of the human immune response, today announced the formation of an advisory board, comprised of Dr. John Lambert and Dr. Anthony Tolcher, to prioritize selection of novel targets for antibody drug conjugates (ADCs) and T cell redirection (TCR) modalities.
By Immunome, Inc. · Via Business Wire · February 8, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
AbbVie (NYSEABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine.
By Immunome, Inc. · Via Business Wire · January 6, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a clinical stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
By Immunome, Inc. · Via Business Wire · November 14, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it is presenting a poster at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston, Massachusetts highlighting the Company’s preclinical data of IMM20059, a novel anti-epsin 1(EPN1) antibody.
By Immunome, Inc. · Via Business Wire · November 9, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced the publication of a peer-reviewed article in Clinical & Translational Immunology characterizing B cell repertoires in tissue samples from patients with breast cancer. In collaboration with groups at the University of Vermont Larner College of Medicine and the University of Pennsylvania, the preclinical study combined next-generation sequence analysis and phage panning to characterize and enrich clonal lineages of tumor-specific B cells in discrete tissues from cancer patients.
By Immunome, Inc. · Via Business Wire · August 23, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
By Immunome, Inc. · Via Business Wire · August 5, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that their cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in pseudovirus testing. IMM-BCP-01 is currently in Phase 1b clinical testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5 and BA.2.
By Immunome, Inc. · Via Business Wire · July 6, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced the first patient has been enrolled in a clinical trial of IMM-BCP-01, a three-antibody cocktail for the treatment of SARS-CoV-2 (COVID-19). Topline data is expected in the second half of this year, which is an update from our prior guidance.
By Immunome, Inc. · Via Business Wire · June 9, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, PhD, President and CEO of Immunome, will present at the Jefferies Healthcare Conference on Thursday, June 9, at 2:30 p.m. ET.
By Immunome, Inc. · Via Business Wire · June 2, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced updates to the ongoing development of its lead oncology program, IMM-ONC-01, a novel immuno-oncology agent that inhibits IL-38, an immunosuppressive cytokine.
By Immunome, Inc. · Via Business Wire · May 23, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potently cleared the Omicron variant (BA.1) of SARS-CoV-2 when tested in vivo in hamsters. Additional in vitro testing of a SARS-CoV-2 pseudovirus also showed that IMM20253, one of the antibodies in Immunome’s cocktail, successfully neutralized the Omicron subvariant (BA.2).
By Immunome, Inc. · Via Business Wire · May 19, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
By Immunome, Inc. · Via Business Wire · May 12, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the fourth quarter ended December 31, 2021 and provided a corporate update.
By Immunome, Inc. · Via Business Wire · March 28, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced in vitro data demonstrating effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two external laboratories (Boston University’s National Emerging Infectious Diseases Laboratories and Washington University1).
By Immunome, Inc. · Via Business Wire · February 8, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced an update regarding its Investigational New Drug (IND) submission for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19).
By Immunome, Inc. · Via Business Wire · January 10, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that members of management will participate in a fireside chat hosted by Cantor Fitzgerald Analyst Brian Cheng on Wednesday, December 8, 2021 at 1:00 p.m. ET.
By Immunome, Inc. · Via Business Wire · December 7, 2021
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon mapping of those mutations and activity against previous and current CDC variants of concern, Immunome expects its antibody cocktail, IMM-BCP-01, to neutralize the Omicron variant. The Company is diligently working to confirm this activity in laboratory testing and expects initial results to be available in January 2022.
By Immunome, Inc. · Via Business Wire · December 1, 2021
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19).
By Immunome, Inc. · Via Business Wire · November 29, 2021
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
By Immunome, Inc. · Via Business Wire · November 15, 2021
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, Ph.D., Immunome’s President and CEO, will present at the Stifel Healthcare Conference on Monday, November 15, 2021 at 8:00 a.m. ET.
By Immunome, Inc. · Via Business Wire · November 9, 2021
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The manuscript is concurrently undergoing scientific peer review for potential publication.
By Immunome, Inc. · Via Business Wire · October 20, 2021
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today made an oral poster presentation on the company’s anti-interleukin-38 monoclonal antibody program at the joint meeting of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 7-10, 2021.
By Immunome, Inc. · Via Business Wire · October 7, 2021
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it will be making an oral poster presentation on the company’s anti IL-38 antibody program at the upcoming joint meeting of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 7-10, 2021.
By Immunome, Inc. · Via Business Wire · September 30, 2021
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, Ph.D., Immunome’s President and CEO, will present at the Cantor Global Healthcare Conference on Wednesday, September 29, 2021, at 8:40 a.m. ET.
By Immunome, Inc. · Via Business Wire · September 22, 2021
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, Ph.D., Immunome’s President and CEO, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Tuesday, September 21, 2021, at 9:55 a.m. ET.
By Immunome, Inc. · Via Business Wire · September 15, 2021